ClinicalTrials.gg
RecruitingNCT07231315INTERACT4 ExpUpdated Oct 26, 2026

INTERACT4 Expansion - Validation Study

An observational study in Intracerebral Hemorrhage, sponsored by The George Institute. Recruiting at 6 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by The George Institute · Observational

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 26, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
163
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Cerebral Hemorrhage with a site in Australia — 5 open to participants now, 6 under way, 2 of them phase 3. Cerebral Hemorrhage · Australia.

Started
2026
the only one that year
Observational
2 of 20
1 open now
Registered
20th of 20
by date
Lead sponsor
9 of 20
The George Institute

Among the 20 studies in Cerebral Hemorrhage with a site in Australia, this one is the only one that started in 2026, is one of 2 observational ones, and was the 20th registered.

Cerebral Hemorrhage

458 studies on the registry are indexed under Cerebral Hemorrhage; 173 are open to participants now.

Browse Cerebral Hemorrhage studies →

Open to participants now

5 of the 20 studies in Cerebral Hemorrhage with a site in Australia are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 115 Cerebral Hemorrhage studies recruiting now, 61 (53%) set no upper age limit and 9 (8%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Cerebral Hemorrhage with a site in Australia, or all of them as a file.
02

Study summary

As an investigator-initiated and conducted, multi-centre, open-label, single-arm prospective observational trial, INTERACT4 Expansion aims to evaluate the feasibility of setting up and conducting a trial that uses a point-of-care GFAP test to identify ICH in patients presenting with acute stroke-like symptoms in the pre-hospital setting.

03

Conditions studied

  • Intracerebral Hemorrhage

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with suspected acute stroke presenting to ambulance services

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults (age ≥18 years);
  2. Acute syndrome that is due to presumed acute stroke, defined as FAST (Face, Arm, Speech, Time) scores of ≥2 with an arm motor deficit;
  3. Time ≤3 hours from last seen well;
  4. Systolic BP (SBP) ≥150mmHg.

Exclusion criteria

Exclusion Criteria:

  1. Participants in coma (no response to tactile/verbal stimulation); or/and do not respond to "P" or "U" on the alert/verbal/painful/unresponsive (APVU) responsiveness scale;
  2. Severe known co-morbid disease (e.g. cancer, chronic airflow disease, severe dementia, severe heart failure, pre-existing disability [needing help]);
  3. Known history of epilepsy or seizure at onset;
  4. Recent head injury (where there is potential for another type of intracranial haemorrhage or head trauma);
  5. Hypoglycaemia (glucose\<4.0 mmol/L) as measured in the ambulance.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
163 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testLVOne

    LVOne is an in vitro diagnostic rapid lateral flow chromatographic immunoassay kit

06

What researchers measure

Primary outcomes

  1. Feasibility of recruitment, assessed by the proportion of enrolled participants over the number of stroke calls in the participating networks during the study period.

    Time frame: Through study completion, an average of 1 year

  2. Feasibility of protocol delivery, assessed by the proportion of participants for whom all required study assessments in the ambulance were completed among those in whom assessments were initiated.

    Time frame: Baseline

Secondary outcomes

  1. Feasibility of GFAP testing in the prehospital setting, defined as the proportion of enrolled participants in whom GFAP testing was successfully completed using the point-of-care device in the ambulance.

    Time frame: Baseline

  2. Proportion of participants without ICH on hospital-based brain CT who are correctly identified as negative based on GFAP point-of-care measurement. (Specificity)

    Time frame: Day 7

  3. Proportion of participants with ICH on hospital-based brain CT who are correctly identified as positive based on GFAP point-of-care measurement. (Sensitivity)

    Time frame: Day 7

  4. Proportion of participants with a positive GFAP point-of-care measurement who are confirmed to have ICH on hospital-based brain CT. (Positive predictive value)

    Time frame: Day 7

  5. Proportion of participants with a negative GFAP point-of-care measurement who are confirmed to not have an ICH on hospital-based brain CT. (Negative predictive value)

    Time frame: From enrolment to initial CT scan up until 7 day assessment

  6. Correlation of GFAP measurement by the point-of-care device against a laboratory assay.

    Time frame: From enrolment to transfer to hospital at day 1

07

Study locations

5 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Mar 2027, 5 months after the start.

Of 88 non-industry observational studies under Cerebral Hemorrhage, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 179. This study's planned 5 months is below that.

Counting every sponsor, half of 90 studies reached it within 62 months; a quarter within 27 and three quarters within 179.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: start Feb 2026 → Sep 2026 and primary completion Nov 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2025
First posted
Nov 17, 2025
StartActual
Sep 18, 2026was Feb 2026
Primary completionEst.
Mar 1, 2027was Nov 2026
CompletionEst.
Jun 1, 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
2 sites added. 4 sites changed recruiting status (3 now recruiting, 1 now not yet recruiting)
Show 4 sites
  • Liverpool Hospital · Sydney, Australiano status→Not yet recruiting
  • Nepean Hospital · Sydney, Australiano status→Recruiting
  • New South Wales Ambulance · Sydney, Australiano status→Recruiting
  • Royal North Shore Hospital · Sydney, Australiano status→Recruiting
Show 2 added (2 Australia)
  • St George Hospital · Sydney, Australia
  • Wollongong Hospital · Sydney, Australia
Oct 26, 2026
Start date
Feb 1, 2026→Sep 18, 2026 (actual)
Oct 26, 2026
Primary completion
Nov 1, 2026→Mar 1, 2027
Oct 26, 2026
Enrollment
465→163
Oct 26, 2026
Primary outcomes
2 added, 1 removed
What changed in the outcomes
  • AddedFeasibility of recruitment, assessed by the proportion of enrolled participants over the number of stroke calls in the participating networks during the study period.Time frame: Through study completion, an average of 1 year
  • AddedFeasibility of protocol delivery, assessed by the proportion of participants for whom all required study assessments in the ambulance were completed among those in whom assessments were initiated.Time frame: Baseline
  • RemovedProportion of participants without ICH on hospital-based brain CT who are correctly identified as negative based on GFAP point-of-care measurement. (Specificity)Time frame: From enrolment to initial CT scan up until 7 day assessment
Oct 26, 2026
Secondary outcomes
3 edited, 1 time frame changed, 1 added, 3 removed
What changed in the outcomes
  • EditedProportion of participants withwithout ICH on hospital-based brain CT who are correctly identified as positivenegative based on GFAP point-of-care measurement. (Specificity)Time frame: From enrolment to initial CT scan up until 7 day assessment → Day 7
  • EditedProportion of participants with a positive GFAP point-of-care measurement who are confirmed to have ICH on hospital-based brain CT. (Positive predictive value)Time frame: From enrolment to initial CT scan up until 7 day assessment → Day 7
  • EditedProportion of participants with a negative GFAP point-of-care measurement who are confirmed to not have an ICH on hospital-based brain CT. (Negative predictive value)Time frame: From enrolment to initial CT scan up until 7 day assessment
  • AddedProportion of participants with ICH on hospital-based brain CT who are correctly identified as positive based on GFAP point-of-care measurement. (Sensitivity)Time frame: Day 7
  • RemovedFeasibility of recruitment, assessed by the proportion of enrolled participants over the number of stroke calls in the participating networks during the study period.Time frame: From enrollment to end of the study.
  • RemovedFeasibility of protocol delivery, assessed by the proportion of participants for whom all required study assessments in the ambulance were completed among those in whom assessments were initiated.Time frame: From enrolment to transfer to hospital at day 1
  • Time frameFeasibility of GFAP testing in the prehospital setting, defined as the proportion of enrolled participants in whom GFAP testing was successfully completed using the point-of-care device in the ambulance.From enrolment to transfer to hospital at day 1 → Baseline
  • Removedother outcomeSensitivity, specificity, positive predictive value, and negative predictive value for identifying ICH using a (+) GFAP combined with a (-) D-dimer result on the point-of-care device, compared with hospital-based brain CT.Time frame: From enrolment to initial CT scan up until 7 day assessment
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    2 sites added. 4 sites changed recruiting status (3 now recruiting, 1 now not yet recruiting)
    Show 4 sites
    • Liverpool Hospital · Sydney, Australiano status→Not yet recruiting
    • Nepean Hospital · Sydney, Australiano status→Recruiting
    • New South Wales Ambulance · Sydney, Australiano status→Recruiting
    • Royal North Shore Hospital · Sydney, Australiano status→Recruiting
    Show 2 added (2 Australia)
    • St George Hospital · Sydney, Australia
    • Wollongong Hospital · Sydney, Australia
    Start date Feb 1, 2026→Sep 18, 2026 (now actual)
    Primary completion Nov 1, 2026→Mar 1, 2027
    Enrollment 465→163
    Primary outcomes 2 added, 1 removed
    What changed in the outcomes
    • AddedFeasibility of recruitment, assessed by the proportion of enrolled participants over the number of stroke calls in the participating networks during the study period.Time frame: Through study completion, an average of 1 year
    • AddedFeasibility of protocol delivery, assessed by the proportion of participants for whom all required study assessments in the ambulance were completed among those in whom assessments were initiated.Time frame: Baseline
    • RemovedProportion of participants without ICH on hospital-based brain CT who are correctly identified as negative based on GFAP point-of-care measurement. (Specificity)Time frame: From enrolment to initial CT scan up until 7 day assessment
    Secondary outcomes 3 edited, 1 time frame changed, 1 added, 3 removed
    What changed in the outcomes
    • EditedProportion of participants withwithout ICH on hospital-based brain CT who are correctly identified as positivenegative based on GFAP point-of-care measurement. (Specificity)Time frame: From enrolment to initial CT scan up until 7 day assessment → Day 7
    • EditedProportion of participants with a positive GFAP point-of-care measurement who are confirmed to have ICH on hospital-based brain CT. (Positive predictive value)Time frame: From enrolment to initial CT scan up until 7 day assessment → Day 7
    • EditedProportion of participants with a negative GFAP point-of-care measurement who are confirmed to not have an ICH on hospital-based brain CT. (Negative predictive value)Time frame: From enrolment to initial CT scan up until 7 day assessment
    • AddedProportion of participants with ICH on hospital-based brain CT who are correctly identified as positive based on GFAP point-of-care measurement. (Sensitivity)Time frame: Day 7
    • RemovedFeasibility of recruitment, assessed by the proportion of enrolled participants over the number of stroke calls in the participating networks during the study period.Time frame: From enrollment to end of the study.
    • RemovedFeasibility of protocol delivery, assessed by the proportion of participants for whom all required study assessments in the ambulance were completed among those in whom assessments were initiated.Time frame: From enrolment to transfer to hospital at day 1
    • Time frameFeasibility of GFAP testing in the prehospital setting, defined as the proportion of enrolled participants in whom GFAP testing was successfully completed using the point-of-care device in the ambulance.From enrolment to transfer to hospital at day 1 → Baseline
    • Removedother outcomeSensitivity, specificity, positive predictive value, and negative predictive value for identifying ICH using a (+) GFAP combined with a (-) D-dimer result on the point-of-care device, compared with hospital-based brain CT.Time frame: From enrolment to initial CT scan up until 7 day assessment
    + 3 other changes: verification date, oversight details and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07231315
Lead sponsor
The George Institute
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Sep 18, 2026
Primary completion
Mar 1, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Craig Anderson, MD
Contact
canderson@georgeinstitute.org.au
+61 4039448107
Cheryl Carcel, MD
Contact
ccarcel@georgeinsitute.org.au

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion